Elaine Sun is a 30-year life sciences and financial industry veteran with a track record of building and creating value for early- to late-stage biopharmaceutical companies. She is currently the Chief Operating Officer and Chief Financial Officer at Mammoth Biosciences, an in vivo gene editing therapeutics company co-founded by Nobel laureate and CRISPR pioneer Jennifer Doudna. She previously was SVP and CFO at Halozyme Therapeutics, a commercial-stage biotechnology company, and served as CFO and Chief Strategy Officer at SutroVax (now Vaxcyte), a developer of innovative vaccines. Earlier in her career, she advised pharmaceutical, biotechnology and medical device companies on M&A and financing transactions valued in excess of $50 billion, including as Managing Director at Evercore Partners and Merrill Lynch. Ms. Sun currently serves on the Board of Dynavax Technologies (NASDAQ:DVAX), a commercial-stage vaccines company as well as Asher Biotherapeutics, a clinical-stage precision oncology company, and holds a BA from Wellesley College and an MBA from Harvard Business School.
